**2.5. Axitinib**

Axitinib is a selective kinase inhibitor that inhibits VEGFR. Axitinib was not superior to best supportive care alone in a randomized phase II trial comparing best supportive care plus axitinib (starting dose 5 mg twice daily) with placebo in 202 patients with advanced HCC who progressed on or were intolerant of one prior antiangiogenic therapy [16]. The difference in median overall survival (the primary endpoint), was not statistically significant (12.7 vs. 9.7).
